CD30-directed Immunoconjugate

Name
CD30-directed Immunoconjugate
Accession Number
DBCAT003493
Description

Not Available

Drugs
DrugDrug Description
Brentuximab vedotinA CD30-directed antibody-drug conjugate used to treat various types of lymphoma.
Drugs & Drug Targets
DrugTargetType
Brentuximab vedotinTumor necrosis factor receptor superfamily member 8target
Brentuximab vedotinCytochrome P450 3A4enzyme
Brentuximab vedotinATP-binding cassette sub-family B member 5transporter